Targeting Multiple Pathophysiological Axes in COPD: Nanomaterial Advances

Area of Science:

• Nanomedicine
• Pulmonary Medicine
• Biotechnology

Background:

• Chronic obstructive pulmonary disease (COPD) presents significant global health challenges due to progressive nature and limited treatment efficacy.
• Current COPD therapies suffer from poor drug bioavailability in the lungs and off-target systemic toxicity.
• Addressing these limitations requires novel therapeutic strategies targeting COPD's complex pathophysiology.

Purpose of the Study:

• To systematically identify and analyze nano-intervention targets specific to COPD pathophysiology.
• To critically evaluate existing respiratory-adaptive nanocarrier systems for COPD treatment.
• To provide a roadmap for advancing nano-interventions towards precision therapeutics for COPD.

Main Methods:

• Systematic identification of COPD-specific nano-intervention targets across four pathophysiological axes: inflammation, redox imbalance, protease-antiprotease homeostasis, and airway remodeling.
• Critical evaluation of nanocarrier systems like polymer nanoparticles (PLGA-PEG) and lipid nanoparticles (LNPs).
• Review of existing literature on nanoparticle efficacy, targeting efficiency, and biocompatibility in pulmonary delivery.

Main Results:

• Identified key nano-intervention targets within COPD's core pathophysiological mechanisms.
• Demonstrated enhanced neutrophil targeting efficiency (6.5-fold) with PLGA-PEG nanoparticles (*p* < 0.001).
• Achieved >90% siRNA-mediated inflammatory gene suppression using lipid nanoparticles (LNPs).
• Highlighted biocompatibility concerns, such as silica nanoparticles increasing TGF-β (1.8-fold, *p* < 0.05).

Conclusions:

• Nano-interventions hold promise for improving COPD treatment by enhancing pulmonary drug delivery and reducing systemic toxicity.
• Challenges in nanoparticle engineering, pulmonary biocompatibility, and regulatory hurdles must be addressed for clinical translation.
• Future research should focus on stimulus-responsive platforms, multidisease targeting, and AI-driven personalized formulations for advanced COPD nanotherapeutics.